Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amneal Pharmaceuticals (AMRX Research Report), Replimune Group ... Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amneal Pharmaceuticals (AMRX Research Report), Replimune Group...

Investors considering a purchase of Replimune Group Inc (REPL) shares, but tentative about paying the going market price of 23.25/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put...

NAARDEN, Netherlands and MUNICH, Germany, May 04, 2023 (GLOBE NEWSWIRE) -- Forbion, a leading European life sciences venture capital firm, announces the appointment of Silva Deelan PhD, as Forbions first Head of Impact & ESG. Silva has over 15 years of experience in ESG integration, sustainability ...

Forbions largest fundraising to date750 million raised in the final close of the Forbion Ventures Fund VI 600 million raised in the final close of the Forbion Growth Opportunities Fund II Brings the total of funds under management at Forbion to 3 billion NAARDEN, The Netherlands and MUNICH, Germany...

WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and...